Semaglutide 10mg

🔬 Semaglutide — Overview

Semaglutide is a synthetic, long-acting peptide analog of glucagon-like peptide-1 (GLP-1) designed to activate the GLP-1 receptor. It was engineered to improve glycemic control, appetite regulation, and body-weight reduction through incretin signaling. Structural modifications give semaglutide high metabolic stability and prolonged circulation time, allowing once-weekly dosing in approved pharmaceutical formulations.

📌 Brief Functional Description

• Incretin signaling: Enhances glucose-dependent insulin secretion and suppresses glucagon release.
• Appetite & satiety regulation: Acts centrally to reduce hunger and caloric intake.
• Gastric emptying modulation: Slows gastric emptying, contributing to post-prandial glucose control.
• Research relevance: Widely studied in metabolic, endocrine, cardiovascular, and obesity research.

🧪 Chemical & Structural Information

🔢 CAS Number

• 910463-68-2

🧬 Molecular Formula

• C₁₈₇H₂₉₁N₄₅O₅₉

⚖️ Molecular Weight

• ≈4,113.6 g/mol (Da)

🧬 Amino Acid Sequence & Structure

• Semaglutide is a 31-amino-acid peptide derived from native GLP-1 with key modifications:
  • Aib (α-aminoisobutyric acid) substitution to resist enzymatic degradation
  • C18 fatty-acid side chain attached via a linker to promote albumin binding
  • C-terminal amidation for enhanced stability
• These changes significantly extend half-life while preserving GLP-1 receptor affinity.

General structural description:

Modified GLP-1 peptide with fatty-acid acylation and enhanced protease resistance 

🧠 Mechanism & Biological Context

• Semaglutide binds to the GLP-1 receptor (a GPCR) on pancreatic beta cells and neurons.
• Receptor activation increases cAMP signaling, leading to insulin secretion in a glucose-dependent manner.
• Central nervous system effects influence satiety centers in the hypothalamus, reducing appetite.
• Albumin binding from fatty-acid acylation accounts for its long plasma half-life and sustained biological action.

⚠️ Safety & Regulatory Notes

• Approved pharmaceutical: Semaglutide is FDA-approved in specific formulations for type 2 diabetes and chronic weight management.
• Prescription medication: Use is regulated and indicated only for approved clinical contexts.
• Gastrointestinal effects are the most commonly reported adverse reactions in clinical use.

🧪 Quick Reference